Rheumatology

General Dermatology

Questions discussed in this category

Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?

How do you optimize retinopathy screening schedules for patients on hydroxychloroquine while also prioritizing cost-effectiveness?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Cost Effectiveness of HCQ Screening.

3 Answers available

Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?

Do you generally feel they work well? Have patients tried using this a few days before an activity, such as skiing? Especially for otherwise healthy, ...

1 Answer available

Does the presence of psoriatic arthritis affect your decision to use an anti-IL-17 or IL-23 drug in your psoriasis patients?

3 Answers available

What is your approach to managing pyoderma gangrenosum recalcitrant to oral steroids?

When do you switch to steroid-sparing medications? What steroid-sparing therapies do you prefer?

7 Answers available

Does IVIG or subcutaneous Ig interfere with monoclonal antibody therapy (i.e. dupilumab, infliximab, rituximab, etc)?

How should IVIG and either biologic injections or infusions be spaced?

2 Answers available

What is your approach to evaluation in patients who present with erythromelalgia?

1 Answer available

How do you evaluate livedo reticularis (not livideo racemosa)?

Does your evaluation hinge on nonresolution with warming? How extensive is your workup?

1 Answer available

If you have clinical suspicion for a paraneoplastic process (e.g. dermatomyositis or pemphigus), what work-up do you pursue?

1 Answer available

Papers discussed in this category

Rheum Dis Clin North Am, 2020 Aug

Risk Factors and Cancer Screening in Myositis.

Rheumatology (Oxford),

A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies.

Clinical pharmacokinetics, 2018-12

Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease.

Frontiers in immunology, 2018

Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin.

Clinical immunology (Orlando, Fla.), 2020 Jul 15

The potential impact of timing of IVIG administration on the efficacy of rituximab for immune tolerance induction for patients with Pompe disease.

The Pediatric infectious disease journal, 2018 Oct

Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2017 Nov 03

Successful IVIG treatment without discontinuation of TNF-α blocker in Guillain-Barre syndrome induced by adalimumab in patient with Crohn's disease.

Annals of the rheumatic diseases, 2024 Mar 18

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.

Ann Rheum Dis, 2020 Dec 17

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.

Arthritis & rheumatology (Hoboken, N.J.), 2021 Apr 26

American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity.

Ophthalmology, 2016-06

Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).

Rheumatology

General Dermatology

Questions discussed in this category

Papers discussed in this category

Related Topics in Rheumatology